Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: Could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?

Clinical and Applied Thrombosis/Hemostasis

Volumn 7, Issue 2, 2001, Pages 141-148

  Koh, S C L ^a   Tham, K F ^a   Razvi, K ^a   Oei, P L ^a   Lim, F K ^a   Roy, A C ^a   Prasad, R N V ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Fibrinolytic; Hemostatic; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; D DIMER; FIBRINOGEN; PLASMINOGEN; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0035081799     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960100700211     Document Type: Article

References (37)

1. The epidemiology of ovarian cancer
2. Fibrin and cancer
3. Cellular mechanisms for the activation of blood coagulation
4. Mechanisms of hypercoagulation in malignancy during chemotherapy
5. Disseminated intravascular coagulation
6. Disseminated intravascular coagulation: Objective criteria for diagnosis and management
7. Alterations of hemostasis associated with malignancy: Etiology, pathophysiology, diagnosis and management
8. Thrombinantithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumors
9. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factor and with survival
10. Coagulation and fibrinolysis in patients with advanced ovarian cancer compared with those with benign cysts
11. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary
12. Tissue factor as a tumor procoagulant
13. Plasminogen activtors and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer
14. Study on the plasma plasminogen activators in patients with malignant gynecologic tumors
15. The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors
16. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer
17. A plasmin generation method for the determination of tissue plasminogen activator (t-PA) activity in blood
18. Thrombelastography in normal subjects and in various clinical states
19. Plasma urokinase activity and antigen levels in normal males, females and in late pregnancy
20. Plasma tissue plasminogen activator inhibitor (t-PAI) activity in normal subjects
21. Abnormalities of blood coagulation in patients with cancer
22. Hemostatic alterations in cancer patients
23. Haemostasis in benign and malignant gynaecological tumors: A pilot study
24. D-dimer: A useful marker of disease in surgery for colorectal cancer
25. Pretreatment plasma levels of fibrinopeptide-1 (FPA), D-dimer (DD), and von Willebrand Factor (vWF) in patients with ovarian carcinoma
26. Activation of blood coagulation in patients with cancer: Trousseau's syndrome revisited
27. Antimetastatic effects associated with platelet function
28. Cellular receptors in the regulation of plasmin generation
29. Relationship between age and plasma t-PA, PA-inhibitor and PA activity
30. Plasma levels of t-PA, free PAI-1 and a complex of t-PA with PAI-1 in human males and females at various ages
31. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer
32. Blood coagulation and thrombosis in patients with ovarian malignancy
33. Low molecular weight heparin (LMWH) in the treatment of patients with acute venous thromboembolism
34. Treatment of deep venous thrombosis with low molecular weight heparins. A metaanalysis